New Tumor-Injected drug aims to rally immune system against cancer

NCT ID NCT04799054

Terminated Disease control Sponsor: Ascendis Pharma Oncology Division A/S Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new drug designed to stimulate the immune system to fight cancer. The drug was injected directly into tumors, either by itself or combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors. The main goals were to find a safe dose and see how well the body handled the treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ascendis Investigational Site

Los Angeles, California, 90067, United States
Ascendis Investigational Site

Orange, California, 92868, United States
Ascendis Investigational Site

Tampa, Florida, 33612, United States
Ascendis Investigational Site

Dallas, Texas, 75235, United States
Ascendis Investigational Site

Dallas, Texas, 75390, United States
Ascendis Investigational Site

Houston, Texas, 77030, United States
Ascendis Investigational Site

Bedford Park, 5042, Australia
Ascendis Investigational Site

Amsterdam, 1066, Netherlands
Ascendis Investigational Site

Rotterdam, 3015 GD, Netherlands
Ascendis Investigational Site

Dalseo-gu, 42601, South Korea
Ascendis Investigational Site

Seocho-gu, 06591, South Korea
Ascendis Investigational Site

Seogu, 49201, South Korea
Ascendis Investigational Site

Seogu, 49267, South Korea
Ascendis Investigational Site

Seongnam, 13620, South Korea
Ascendis Investigational Site

Seoul, 03722, South Korea
Ascendis Investigational Site

Seoul, 05505, South Korea
Ascendis Investigational Site

Seoul, 06273, South Korea
Ascendis Investigational Site

Suwon, 16247, South Korea
Ascendis Investigational Site

Suwon, 16499, South Korea
Ascendis Investigational Site

Barcelona, 08003, Spain
Ascendis Investigational Site

Barcelona, 08028, Spain
Ascendis Investigational Site

Barcelona, 08035, Spain
Ascendis Investigational Site

Barcelona, 08908, Spain
Ascendis Investigational Site

Madrid, 28027, Spain
Ascendis Investigational Site

Madrid, 28040, Spain
Ascendis Investigational Site

Madrid, 28041, Spain
Ascendis Investigational Site

Madrid, 28050, Spain
Ascendis Investigational Site

Málaga, 29010, Spain
Ascendis Investigational Site

Murcia, 30120, Spain
Ascendis Investigational Site

Pamplona, 31008, Spain
Ascendis Investigational Site

Seville, 41009, Spain
Ascendis Investigational Site

Valencia, 46009, Spain
Ascendis Investigational Site

Taichung, 404, Taiwan
Ascendis Investigational Site

Taichung, 40705, Taiwan
Ascendis Investigational Site

Tainan, 704, Taiwan
Ascendis Investigational Site

Taipei, 112, Taiwan
Ascendis Pharma Investigational Site

Duarte, California, 91010, United States
Ascendis Pharma Investigational Site

San Francisco, California, 94158, United States
Ascendis Pharma Investigational Site

Chicago, Illinois, 60637, United States
Ascendis Pharma Investigational Site

Iowa City, Iowa, 52242, United States
Ascendis Pharma Investigational Site

Louisville, Kentucky, 40202, United States
Ascendis Pharma Investigational Site

Canton, Ohio, 44718, United States
Ascendis Pharma Investigational Site

Cincinnati, Ohio, 45219, United States
Ascendis Pharma Investigational Site

Cleveland, Ohio, 44106, United States
Ascendis Pharma Investigational Site

Pittsburgh, Pennsylvania, 15232, United States
Ascendis Pharma Investigational Site

Knoxville, Tennessee, 37920, United States
Ascendis Pharma Investigational Site

Fairfax, Virginia, 22031, United States
Ascendis Pharma Investigational Site

Wollongong, New South Wales, 2500, Australia
Ascendis Pharma Investigational Site

Frankston, Victoria, 3199, Australia

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC HPV-ASSOCIATED CANCERS LOCALLY ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NEOADJUVANT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) NEOADJUVANT MELANOMA